Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, October 2015

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

twitter: 3 X users

patent: 15 patents

Readers on

mendeley: 46 Mendeley

So far, Altmetric has seen 15 patents that reference this research output.

Constrained conditionally activated binding proteins

Grant US-12478673-B2

United States of America

25 Nov 2025

Constrained conditionally activated binding proteins

Grant US-12128102-B2

United States of America

29 Oct 2024

Chimeric polypeptide assembly and methods of making and using the same

Grant US-11981744-B2

United States of America

14 May 2024

Bispecific antibody which binds to CD40 and EpCAM

Grant US-11773180-B2

United States of America

03 Oct 2023

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 11 additional patents.